contact us on e-mail: we@nosamplio.com

data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs=

2024: we supported Sinocare to an exclusive, European distribution agreement for a new CGM

2024: we supported Sinocare to an exclusive, European distribution agreement for a new CGM

2024: we supported Sinocare to an exclusive, European distribution agreement for a new CGM

2024: we supported Sinocare to an exclusive, European distribution agreement for a new CGM

2024: we supported Sinocare to an exclusive, European distribution agreement for a new CGM

2024: we supported Sinocare to an exclusive, European distribution agreement for a new CGM

2022: we supported ATGC to an exclusive, European, novel pharmaceutical, out-licensing agreement

2022: we supported ATGC to an exclusive, European, novel pharmaceutical, out-licensing agreement

2022: we supported ATGC to an exclusive, European, novel pharmaceutical, out-licensing agreement

2022: we supported ATGC to an exclusive, European, novel pharmaceutical, out-licensing agreement

2022: we supported ATGC to an exclusive, European, novel pharmaceutical, out-licensing agreement

2022: we supported ATGC to an exclusive, European, novel pharmaceutical, out-licensing agreement

pharmaceutical and medical device

pharmaceutical and medical device

pharmaceutical and medical device

we have  supported numerous human health brands including medicines, injectables, medical devices, aesthetics devices, cosmetics, botanicals & nutraceuticals. 

Rx and private-pay specialists.

strategic marketing

pharmaceutical and medical device

pharmaceutical and medical device

we provide professional insight for human health projects including strategic planning, market access, patient access, launch, re-launch & mature commercial strategies.

global expertise

pharmaceutical and medical device

global expertise

 we have sector expertise supporting Korean, Taiwanese, Chinese & Japanese companies reach their target audience in Europe, 

MENA & the Americas.

nosamplio is delighted to represent Sinocare Meditech Inc. supporting European iCan business development, market-access, marketing, advocacy & sales

    success stories • a pharmaceutical out-licensing outcome

    Global out-licensing

    ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom. www.relifecompany.com 

    Pharmaceutical out-licensing

    Nosamplio provided ATGC with specialist pharmaceutical out-licensing consultancy to secure the Exclusive European Licensing Agreement with RELIFE

    https://www.menarini.com/en-us/news/news-detail/atgc-co-ltd-license-agreement-grants-relife-srl-exclusive-rights-to-register-promote-distribute-and-market-the-novel-botulinum-toxin-type-a-atgc-100-in-europe-and-the-united-kingdom




    ATGC Co., Ltd.

    ATGC is an advanced biotechnology company, Korea based R&D with a pipeline of pharmaceutical projects. ATGC developed ATGC-100 a novel botulinum toxin type A for medical aesthetics indications www.atgcbio.com


    success stories • global business development solutions

    Business development services for a large-cap Korean pharmaceutical company

    GC녹십자웰빙

    GCWB204’ 암악액질 치료제 가능성 확인

    We provide Green Cross with global BD & Licensing services


    regional out-licensing solutions

    Business development & Licensing for Korean pharmaceutical companies

    Global out-licensing for a commercial stage asset within gastroenterology h

    http://gkpharm.co.kr

    We provide GK Pharm with global Licensing consultancy services

    OnePrep 1.38

    Highly effective, easy-to-drink bowel preparation, on-the-day of colonoscopy for patient convenience

    Licensing Life Science©

    Connect with us on Linkedin

    Licensing Life Sciences team

    Lee Taylor

    Dr. Giuseppe Di Benedetto M.D., Ph.D.

    Dr. Giuseppe Di Benedetto M.D., Ph.D.

    Founding Principal

    mob: +44 7714 777 727

    Dr. Giuseppe Di Benedetto M.D., Ph.D.

    Dr. Giuseppe Di Benedetto M.D., Ph.D.

    Dr. Giuseppe Di Benedetto M.D., Ph.D.

    Giuseppe is a qualified medical practitioner with extensive Country specific pharmaceutical compliance experience

    Frankie Neal

    Dr. Giuseppe Di Benedetto M.D., Ph.D.

    Frankie Neal

    Frankie has extensive European & global pharmaceutical marketing experience. He provides clients with strategic marketing 

    and forecasting insights

    Zak Farah

    Philip Tomlinson

    Frankie Neal

    Zak provides client business development. His experience includes pharmaceutical licensing, orphan drugs and life science business intelligence services

    Philip Tomlinson

    Philip Tomlinson

    Philip Tomlinson

    Phil has significant pharmaceutical & medical device partnerships experience. He provides nosamplio clients with support for Business Development & Licensing projects

    Steven Church

    Philip Tomlinson

    Philip Tomlinson

    Steve is MD of Audience Healthcare a markets & target customer insights provider

    Harrison Taylor

    Licensing Life Sciences©

    Harrison Taylor

    Harrison provides in-house social, digital and traditional marketing and communications services for our clients

    Jack Taylor

    Licensing Life Sciences©

    Harrison Taylor

    Jack provides in-house  legal expertise.
    His experience includes 

    pharmaceutical intellectual property. 

    Jack is LLB Law  (York, Eng).

    Licensing Life Sciences©

    Licensing Life Sciences©

    Licensing Life Sciences©

    medical device and  pharmaceutical business development & licensing solutions

    LICENSING LIFE SCIENCES ©

    Stamford, United Kingdom

    +44(0)1780 723 800

    Nosamplio Limited

    Registered in England, Company number 12034395

    EORI: GB344603024000. ICO Registered ZB113191

    © 2018 Nosamplio Limited - All Rights Reserved

    This website uses cookies.

    We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

    Accept